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Interferon signalingRNA viruses have rapidly evolving genomeswhich often allow cross-species transmission and frequently generate
new virus variants with altered pathogenic properties. Therefore infections by RNA viruses are a major threat to
human health. The infected host cell detects trace amounts of viral RNA and the last years have revealed common
principles in the biochemical mechanisms leading to signal ampliﬁcation that is required for mounting of a pow-
erful antiviral response. Components of the RNA sensing and signaling machinery such as RIG-I-like proteins,
MAVS and the inﬂammasome inducibly form large oligomers or even ﬁbers that exhibit hallmarks of prions. Fol-
lowing a nucleation event triggered by detection of viral RNA, these energetically favorable and irreversible poly-
merization events trigger signaling cascades leading to the induction of antiviral and inﬂammatory responses,
mediated by interferon and NF-κB pathways. Viruses have evolved sophisticated strategies to manipulate these
host cell signaling pathways in order to ensure their replication. We will discuss at the examples of inﬂuenza
andHTLV-1 viruses howa fascinating diversity of biochemicalmechanisms is employed by viral proteins to control
the NF-κB pathway at all levels.
© 2014 Elsevier B.V. All rights reserved.1. Genome variability of RNA viruses
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-giessen.de (M.L. Schmitz).double-stranded (ds)) and their replicationmechanism [1]. RNA viruses
are characterized by their pronounced genetic variability which is at-
tributable to various reasons: (i) In contrast to DNA, the spontaneous
deamination of cytosine into uracil is not corrected by proofreading
enzymes. (ii) The viral RNA polymerases lack proofreading activity,
resulting in limited replication ﬁdelity. This leads to a high frequency
of nucleotide misincorporation, the rapid accumulation of mutations
and the generation of viral quasispecies. (iii) In addition, RNA recombi-
nation may occur in cells co-infected by related viruses. Recombination
takes place during RNA synthesis and involves a template-switch of the
viral polymerase, thus resulting in further changes of the viral genome.
(iv) Some RNA viruses such as inﬂuenza viruses have segmented
genomes thatmay undergo reassortment upon infectionwith closely re-
lated viruses. These mechanisms lead to a fast evolution of RNA viruses
and allow the acquisition of novel pathogenic and biological proper-
ties [2,3]. Thus, many RNA viruses including inﬂuenza, human T cell
leukemia virus (HTLV) and severe acute respiratory syndrome (SARS)
corona viruses are associated with severe or even fatal diseases. The
high genetic variability of RNA viruses also allows transmission between
different animal species and man. The reassortment between animal
and human viruses was mainly responsible for the generation of novel
inﬂuenza A viruses (IAVs) such as the infamous H1N1 strain that caused
the 1918 ﬂu pandemic responsible for the death of millions of infected
people [4].
The infection with RNA viruses leads to the induction of signaling
cascades in the infected host cell. The RNA viruses are recognized by
specialized host cell proteins, thus triggering the activation of kinases
and transcription factors which in turn mount an antiviral response as
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veloped multitudinous different strategies to disable the production
and activities of IFNs. In addition, viruses have learned to usurp host
cell signaling pathways to promote their own replication [7].
Recent progress in the identiﬁcation of proteins recognizing viral
RNA and the host cell machinery employed by the virus has broadened
our understanding of themolecularmechanisms occurring during virus
infection. In addition, host cell factors are ideal targets for therapeutic
intervention, as the genetic ﬂexibility of viral target structures frequent-
ly allows the generation of escapemutants.Wewill discuss recent prog-
ress at the example of twowell-studied viruseswith a broad biomedical
relevance: IAV as an example of a fast replicating lytic virus that kills the
infected cell early after infection and HTLV-1 as a paradigm for a slow
growing virus that persists for many years in CD4+ T lymphocytes and
may lead to their oncogenic transformation.
2. Detection of RNA viruses by host cell proteins
The RNA sensingmachinery has a very difﬁcult task, as it must be ro-
bust enough to ignore background signals that could lead to receptor
misﬁring and induction of the innate immune response, which could
potentially lead to autoimmune diseases. On the other hand, virus inva-
sionmust be recognized at the very early stages in order to ensure an ef-
ﬁcient mounting of the IFN response to protect the cells before the viral
infection has overwhelmed the cells. Thus, only 20 molecules of viral
RNA in a cell are sufﬁcient to trigger the detectable activation of the
transcription factor IRF3 (interferon regulatory factor 3) and the induc-
tion of the IFN response [8]. This extraordinary sensitivity is due to a cas-
cade of signal multipliers that use a common principle: the generation
of homopolymers by prion-like polymerization [8–13]. This architectur-
al feature allows for ultrasensitive responses by a self-perpetuating
mechanism of signal ampliﬁcation. As schematically displayed in
Fig. 1, this principle is used at several levels of the signaling cascade
from sensing of RNAs to the activation of transcription factors such as
NF-κB (nuclear factor κB). The activated transcription factors then coop-
erate to trigger the expression of IFN genes. These cytokines then not
only elicit the induced expression of IFN-stimulated genes in the infect-
ed cell, but also acts in a paracrine fashion at the surrounding cells. This
causes an antiviral state that serves to restrict viral spreading [6,14].
In a ﬁrst step, viral RNAs need to be detected by receptors that sur-
vey the extracellular, vacuolar, and cytosolic compartments for signs
of virus infection. Membrane-bound toll-like receptors (TLRs) comprise
the ﬁrst identiﬁed pattern recognition receptor (PRR) family that is spe-
cialized in the recognition of RNA [15,16]. TLR3 and TLR7/8 are inserted
in membranes in a way that the RNA-recognition domains face towards
the extracellular space or to the endosomal lumen. This orientation
allows the sensitive detection of viral RNA at the cell surface or of
pathogen-derived RNA in the endosomes. TLR3 recognizes speciﬁcally
not only viruseswith a dsRNA genomeor dsRNA intermediates generat-
ed during virus replication, but also mRNAs [15,17,18]. The stretches of
virus-derived dsRNA leading to TLR3 activation are much longer than
the short dsRNA structures (such as secondary clover-leaf structure of
transfer RNA) that are present in uninfected cells. Therefore, this recep-
tor is a bona ﬁde PRR that can discriminate between viral and host cell
RNA [19]. In contrast to TLR3, the TLR7 and TLR8 receptors bind ssRNA
that is rich in guanosines/uridines or uridines [20,21] and are thus un-
able to distinguish between pathogen and self-nucleic acids. However,
as the endosomes of uninfected cells do not contain signiﬁcant amounts
of RNA, the limited speciﬁcity of TLR7/8 does not result in receptor
misﬁring. TLR 1, 2 and 5–9 signal via MyD88 (myeloid differentiation
primary response gene 88), an adapter protein that contributes to the
protection from primary IAV infection [22].
The detection of viral RNA in the cytosol is mediated by the family of
RIG-I (retinoic acid-inducible gene I)-like receptors (RLRs) and also by
further cytosolic proteins. As the cytosolic localization of these receptors
frequently exposes them to host cell RNA, signaling from these proteinsis restricted by twomechanisms: (i) their basal expression is further in-
duced and (ii) they havemechanisms to discriminate between viral and
host cell RNA. The mammalian RLR family consists of three central
members, namely RIG-I, MDA5 (melanoma differentiation factor 5),
and LGP2 (laboratory of genetics and physiology 2) [23]. They belong
to the DExD/H-box family of helicases and harbor two helicase domains
followed by a C-terminal domainwhich contributes to ligand speciﬁcity.
Only RIG-I andMDA5 have two adjacent CARDs (caspase activation and
recruitment domains), which allow coupling to downstream signaling
adaptors [24]. In uninfected cells, intramolecular interactions between
the CARD and the C-terminal domainmaintain RIG-I in a closed, inactive
conformation. RIG-I binds preferentially to dsRNAwith blunt ends and a
triphosphate (ppp) moiety at the 5′ end [25,26]. The requirement for a
5′ppp allows to discriminate between self and non-self, as the phos-
phates of host cell mRNAs are either masked by a 7-methyl-guanosine
cap (mRNA) or removed in the case of tRNA and rRNA. In addition,
RIG-I can sense RNAswith complementary 5′ and 3′ ends that hybridize
to form a “panhandle” structure as they occur for many viral genomes,
including those of IAV [26]. After binding of RIG-I to its cognate RNA,
the CARDs are released from their inhibitory association with the
helicase domain [27]. The RNA-bound RIG-I monomers then hydrolyze
ATP to assemble into a ﬁlament that propagates from the dsRNA ends
to the interior [12,13]. RIG-I is further activated upon K63-linked
polyubiquitination, where non-covalent binding of three chains of
K63-branched ubiquitin to the tandem CARDs allows the formation of
RIG-I tetramers which are required for downstream signal activation
[28]. Activated and ubiquitinated RIG-I can then bind to its downstream
effector MAVS (mitochondrial antiviral signaling protein) to induce ac-
tivation of IRF and NF-κB transcription factors, ultimately resulting in
the expression of IFN encoding genes. The agonistic RNAs leading to
MDA5 activation are not as clearly deﬁned as in the case of RIG-I. A de-
termining factor is the length of the activating dsRNA with longer
nucleic acids being more efﬁcient in MDA5 activation [29]. Structural
studies with dsRNA-boundMDA5 show that the receptor cooperatively
assembles in a head-to-tail fashion along the length of dsRNA to form a
ﬁlament-like structure [30]. These multiple protein–protein interac-
tions are mainly mediated by the tandem CARD. Accordingly, dsRNA
serves as a signaling platform allowing the organized assembly of
MDA5 ﬁlaments to activate the downstream signaling molecule
MAVS. Another RNA sensor is LGP2, but the nature of the agonistic
RNAs is not well studied and its regulatory role in antiviral immune re-
sponses does not provide a coherent picture [31].
Cytosolic RNA sensing also employs DExD/H-box helicases outside
the RLR helicase subfamily. This group comprises DDX3 (DEAD (Asp-
Glu-Ala-Asp) box helicase 3), DHX9 (DEAH (Asp-Glu-Ala-His) box
helicase 9) and the DDX1–DDX21–DHX36 complex [32]. DDX3 binds
RNA and regulates replication of human immunodeﬁciency virus [33],
but this protein also plays important functions that are independent
from its ability to bind RNA. For example, DDX3 has been identiﬁed as
a regulatory subunit of casein kinase 1 in the Wnt-β-catenin signaling
pathway [34]. DDX3 and DHX9 sense viral RNA and then couple to
MAVS in order to induce IFN expression [35,36]. The DDX1–DDX21–
DHX36 complex functions as a RNA sensor and associates with further
adaptor proteins to activate the type I IFN response [37].
3. Virus-induced activation of host cell transcription factors and
the inﬂammasome
An important signal integrator for the activated RNA receptors is the
mitochondrial adaptor protein MAVS, which relays the signals obtained
from the RNA sensors to the host cell signaling cascades. The majority of
this protein is found at the outside ofmitochondria, while small amounts
have also been described in association with peroxisomes [38] and the
ER [39]. In vitro experiments showed that RNA-bound RIG-I activates
the adaptor protein MAVS by inducing its aggregation by prion-like
polymerization in the presence of K63-linked polyubiquitin [10,28].
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molecular-weightMAVS polymers. The polymerization process critically
depends on the presence of an N-terminal CARD in MAVS that serves as
a prion domain and is thus required for the polymerization process.
Polymerized MAVS then triggers activation of various downstream
responses such as the inﬂammasome and the transcription factors IRF
and NF-κB.
An initial step in MAVS-mediated NF-κB activation is the recruitment
ofmultiple ubiquitin E3 ligases including TRAF2 (TNF receptor-associated
factor 2) and TRAF6 [40]. TRAF6-mediated K63-ubiquitination creates
docking sites for proteinswith a ubiquitin-binding domain, thus fostering
protein/protein interactions and allowing for the induced proximity of
signaling proteins mediating NF-κB activation [32]. The central step in
the canonical NF-κB pathway is the activation of the IκB kinase (IKK)
complex, which is composed of the kinases IKKα and IKKβ and the
scaffold protein NEMO (NF-κB essential modulator). The activated IKKFig. 1. Sensing of viral RNA and induction of the host cell defense. The inducible aggregation
TRAF2/6, TRAF3 activates the kinases TBK1 and IKKε. These kinases phosphorylate IRF transcr
in the proteins are shown in colors. The inﬂammasome can be also activated upon associationwcomplex phosphorylates the inhibitory IκB (inhibitor of NF-κB), leading
to its subsequent proteolytic elimination, which then allows the DNA-
binding subunits of NF-κB to enter the nucleus and to bind to DNA [41].
MAVS polymerization leads to a TRAF3 dependent activation of the ki-
nases IKKε/TBK1 (IκB kinase ε/TANK-binding kinase), which are activat-
ed by transautophosphorylation [42–45]. The activated IKKε/TBK kinases
in turn phosphorylate IRFs, thus causing their dimerization, nuclear
translocation and the induction of target gene transcription [46]. The
IRF and NF-κB transcription factors bind cooperatively to the IFN-β
enhancer and recruit accessory proteins to trigger IFN-β expression [47].
Besides the activation of IRF/NF-κB transcription factors, MAVS can
also activate the inﬂammasome, a multi-protein complex that catalyzes
the conversion of pro-caspase-1 to active caspase-1, which then con-
verts pro-interleukin-1β (pro-IL-1β) into the mature cytokine to trigger
inﬂammation [48,49]. Inﬂammasomes are typically composed of the
adaptor protein ASC (apoptosis-associated speck-like protein containingof RLRs, MAVS and the inﬂammasome is displayed. While NF-κB activation proceeds via
iption factors, thus allowing for their dimerization and DNA-binding. Important domains
ith themitochondrialMAVS protein, but this process is not displayed for the sake of clarity.
Fig. 2. Schematic display of IKK substrates. Arrows point to the different IKKα/IKKβ
substrates; the biological functions of the substrates are also indicated.
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sensors such as NLRP3 (NLR family, pyrin domain containing 3) or
AIM2 (absent in melanoma 2). Many viruses including IAV activate
the inﬂammasome typically via NLRP3 [50,51]. While the ASC adaptor
contains a CARD and a pyrin domain, the NLRP3 sensor contains a
pyrin domain that allows interaction with ASC. RIG-I can activate the
inﬂammasome not only by a MAVS-independent pathway [52], but
also via NLRP3 recruitment of MAVS to mitochondria [53,54]. The in-
ducible attachment to mitochondria depends on the N-terminal part
of NLRP3, reinforcing the notion that homotypic interactions between
pyrin domains or CARDs are essential for virus-induced signaling
cascades. Two recent studies show that pyrin domain and CARDs of
AIM2 and NLRP3 can form ﬁlaments which, in turn, assemble the CARD
of the ASC adapter. At the end of this cascade the CARD ﬁlaments of
caspase-1 cluster and lead to cleavage of the pro-caspase [9,11]. Formal
proof for the formation of these ASC polymers in virus-infected cells is
still missing. In summary, inducible ﬁlament formation occurs at several
steps of the RNA virus-induced signaling cascade. A more general ques-
tion relates to the reversibility of aggregate formation, which may be
achieved by proteolysis or autophagy. It also remains unknownwhether
there is a “molecular memory” for the signaling complexes. Also the
exact composition and stoichiometry of the multi-protein aggregates
that are inducibly formed during these signaling processes are not well
understood. For example it is known that RIG-I binding toMAVS initiates
the recruitment of N30 interacting partners [55]. However, the exact
order of binding and the occurrence of distinct interactomes have not
been studied.
4. The NF-κB pathways
Exposure of cells to perilous agents such as damage-associated and
pathogen-associated molecular patterns leads to the induction of sig-
naling cascades which ultimately leads to NF-κB activation [41]. Three
major pathways mediating NF-κB activation have been identiﬁed: the
so-called canonical and noncanonical pathways and the atypical NF-κB
activation pathway [41]. All these NF-κB activating pathways have in
common that they lead to the generation of DNA-binding dimers,
which are retained in the cytosol of unstimulated cells by association
with inhibitory IκB proteins. The canonical NF-κB activation pathway
is activated by the IKK complex [56]. Upstream signals lead to the
attachment of K63-branched polyubiquitin chains to NEMO and further
proteins, which enhances association of proteins containing ubiquitin-
binding domains such as TAB2 (TGF-β activated kinase binding protein
2). This in turn allows the recruitment of the TAB2 interacting kinase
TAK1 (TGF-β activated kinase 1), which activates the IKKs by trans-
phosphorylation of serines in the activation loop [57]. The active IKKs
phosphorylate IκBα in order to allow its subsequent phosphorylation-
dependent ubiquitination and proteolytic degradation, thus releasing
the DNA-binding NF-κB dimer from its inhibitor. While the relevance
of IKKβ for IκBα phosphorylation has been demonstrated in knockout
animals [58], a number of studies have revealed that the canonical
IKKs can phosphorylate many more cytoplasmic and nuclear substrate
proteins that are distinct from IκB and NF-κB proteins. Thus the IKKs
serve to relay and coordinate NF-κB with other signaling pathways
such as insulin andWnt signaling [59,60]. This intricate crosstalk serves
to shape the diverse biological functions of NF-κB into context-speciﬁc
responses [61]. A representative selection of IKK substrates and the
affected signaling pathways is represented in Fig. 2.
The noncanonical NF-κB pathway is induced by speciﬁc members of
the TNF (tumor necrosis factor) cytokine family, including the CD40
ligand. The key feature of the noncanonical pathway is the processing
of the precursor p100 protein by the ubiquitin/proteasome system
[62,63]. In comparison to the canonical pathway, this pathway is inde-
pendent of IKKβ or NEMO, whereas the stabilization of NIK (NF-κB-
inducing kinase) and IKKα is essential. Phosphorylation of p100 at
several serines in the C-terminus allows for subsequent ubiquitinationof p100 at K855 and processing of the precursor to the NF-κB subunit
p52 [64,65]. The released p52 subunit is then dimerizing with the
RelB subunit to form p52/RelB heterodimers [66]. The transcriptional
response byp52/RelB dimers is distinct from that induced by the canon-
ical, IκBα-regulated pathway which typically leads to the generation of
p50/p65 dimers.
The atypicalNF-κB activation pathway is activatedwithDNAdamage
where lesions are sensed by poly(ADP-ribose)-polymerase-1 (PARP-1).
This enzyme synthesizes poly(ADP-ribose), thus allowing the dynamic
assembly of a protein complex containing NEMO, PIASy (protein inhibi-
tor of activated STAT y), and the DNA damage-responsive kinase ataxia-
telangiectasia mutated (ATM) [67]. PIASy then triggers the attachment
of SUMO (small ubiquitin-related modiﬁer) to NEMO [68], followed by
phosphorylation and consequent ubiquitination [69]. A fraction of
activated ATM is also traveling to the cytosol where TRAF6-dependent
activation of the TAK1/TAB2 and the IKK complex takes place. This
activation depends on monoubiquitination of NEMO [70]. As a result of
these processes which are reviewed in more detail elsewhere [71], the
activated IKKs lead to the generation of DNA-binding NF-κB dimers
which can be further regulated in the DNA damage response by IKKε-
mediated phosphorylations [72].
Active NF-κB acts as a transcription factor that induces hundreds of
genes as part of an adjustment program serving to copewith the danger
and stress signals leading to NF-κB activation. Among the NF-κB target
genes are regulators of inﬂammatory cytokines (e.g. IL-8), cell survival,
proliferation and cell surface proteins [73]. Accordingly, NF-κB-induced
gene products are important to build a ﬁrst line of defense against in-
vading pathogens. As all viruses inevitably induce NF-κB activity, they
have developed strategies to control NF-κB activity or even to abuse
its activity to sustain transcription of viral genes by using NF-κB DNA
binding sites in their promoters [74,75].
5. The diverse functions of NF-κB in IAV infection
IAVs primarily infect not only lung epithelial cells, but also macro-
phages and recruited leukocytes can be infected [76]. IAVs have a seg-
mented genome consisting of eight negative strand RNAs. The virion
RNA (vRNA) is used as a template for transcription to generate viral
mRNA and complementary RNA (cRNA), respectively. While the cRNA
is used as a template for vRNA synthesis, the mRNA can be translated
to generate viral proteins [77,78]. IAVs encode at least 10 viral proteins
including the regulatory nonstructural protein 1 (NS1), while some
strains express the additional proteins PB1-F2 (polymerase basic pro-
tein 1-frame 2) and PB1 N40. It is now known for almost two decades
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for IAV replication and spreading is still not understood.
5.1. IAV supporting functions of NF-κB
A number of studies suggest that IAV-elicited NF-κB activity helps in
virus replication and spreading, based on the ﬁnding that NF-κB inhibi-
tion also impairs IAV propagation [81–85]. A seminal paper showed that
inhibition of IKK activity by the small molecule inhibitors BAY11-7085
and BAY11-7082 severely impaired IAV infection of human lung carci-
noma cell lines [86]. This study also described that an infection with
vaccinia virus was not NF-κB-dependent, demonstrating that this tran-
scription factor is speciﬁcally required for IAV infection. This basic ﬁnd-
ing was conﬁrmed by several independent follow-up studies which
showed that other IKK inhibitors such as acetyl salicylic acid and
SC75741 efﬁciently block IAV propagation [81,84]. Along this line, inhi-
bition of NF-κB by expression of a dominant-negative IKKβmutant or a
non-degradable IκBαmutant also resulted in diminished IAV replica-
tion in lung A549 cells, further indicating that NF-κB activity promotes
efﬁcient IAV production [87]. Since NF-κB is responsible for themajority
of IAV-elicited gene expression [88], the beneﬁcial effect of IKK inhibi-
tionwill be relevant not only for IAV-infected cells but also for neighbor-
ing cells which are exposed to exaggerated concentrations of cytokines
and chemokines that can cause severe lung damage. The IKK inhibitor
BAY11-7082 impairs IAV replication not only in cultured cells but also
in mouse models. Intraperitoneal administration of the inhibitor causes
impaired cytokine expression and reduced virus titers in the bronchoal-
veolar lavage of IAV-infected mice [85]. Mice lacking the cytosolic pro-
tein kinase RIPK2 (receptor-interacting protein kinase 2) show signs
of hyperinﬂammation along with increased NF-κB activity and expres-
sion of cytokines and chemokines. Consistent with the notion of virus-
supportive NF-κB signaling these animals are hypersusceptible to IAV
infection [89]. The molecular mechanisms employed by NF-κB to
support IAV infection are not well understood. One report shows that
SC75741 efﬁciently impairs IAV-induced expression of cytokines and
pro-apoptotic factors such as TNF-related apoptosis inducing ligand
(TRAIL) or the CD95 ligand. As these ligands trigger the activation of
caspases, also the caspase-mediated nuclear export of viral ribonucleo-
proteins is downregulated [81]. Another study using the IKK inhibitor
BAY11-7082 did not observe effects on nucleocytoplasmic trafﬁcking
of the viral ribonucleoprotein complex [83]. These authors rather re-
ported that the NF-κB inhibitor pyrrolidinedithiocarbamate impairs
vRNA synthesis, but the limited speciﬁcity of this compound raises the
need for further experiments to substantiate these results. This work
also showed that overexpression of p65 activates IAV transcription
from the cRNA promoter [83], but themolecularmechanisms employed
by p65 are not clear. It would be interesting to know whether p65 has
the ability to bind to RNA, as it was previously shown for the NF-κB sub-
unit p50 [90]. Members of the NF-κB activation pathway were also
found in RNAi-based genome-wide screens that were conducted to
identify host factors involved in virus replication. From the large
number of proteins that are involved in NF-κB activation only the
kinases IKKα and IKKε were detected in more than one screen [91].
While these papers collectively show a proviral function of NF-κB,
another study failed to support this notion. Inhibition of NF-κB in
A549 cells upon expression of a non-degradable IκBαmutant reduced
IAV-induced expression of proinﬂammatory cytokines, but did not
affect virus replication [92].
5.2. IAV inhibiting functions of NF-κB
Several reports note an antiviral function of NF-κB. Myeloid cells
lacking the gene encoding the NF-κB inhibitory A20 protein show exag-
gerated NF-κB activation after IAV infection. As expected, these cells
produce increased levels of proinﬂammatory cytokines and type I IFN.
However, knockout of A20 in myeloid cells leads to protection of miceagainst lethal IAV infection, thus pointing to an antiviral role of increased
NF-κB activity [93]. The antiviral function of NF-κB most probably relies
on its ability to induce the expression of inﬂammatory mediators that
help to clear the infection. This notion is supported by experiments
where the administration of 5′ppp RNA to cells or mice causes the RIG-
I-mediated induction of inﬂammatory and IFN-stimulated genes. This
induction of innate immunity protected the cells and animals from a
subsequent infection with IAVs [94], showing the antiviral effects of in-
ﬂammatory mediators. These results also imply that an imbalance be-
tween the harmful and beneﬁcial effects of inﬂammatory mediators
contributes to the pathogenesis of inﬂuenza. How can these various re-
sults be reconciled and explained? It is important to note that most
NF-κB signaling proteins relay to further information processing path-
ways. As schematically depicted in Fig. 2, IKKα and IKKβ phosphorylate
many other substrate proteins beyond IκBα [59,60]. These substrate pro-
teins allow a close coordination of NF-κB signaling with other pathways
and this crosstalk serves to shape the diverse biological functions of
NF-κB [61]. As IKK inhibition will also necessarily impinge on further
pathways, the antiviral function of IKK inhibitors may not exclusively
be attributable to NF-κB inhibition. In the future it will be important to
investigate the contribution of NF-κB-dependent gene expression on
IAV infection by targeting downstream effectors such as the DNA-
binding subunits. Another important aspect relates to the infection
models. In the primary phase of inﬂuenza virus infection a limited
amount of IAVs infects lung cells including alveolar macrophages
that are among the ﬁrst cells that encounter infectious IAV particles
[95]. It is conceivable that NF-κB is antiviral during this initial phase
upon generation of inﬂammatory mediators attracting innate immune
cells (e.g. neutrophils and monocytes) and by triggering expression of
cytokines and antiviral IFN. It was shown that cytokines and soluble
mediators from H5N1-infected human macrophages can activate the ex-
pressionof RNA-sensing proteins such as RIG-I,MDA5, and TLR3 [96]. This
paracrine effect allows uninfected cells to detect IAV infectionwith higher
sensitivity and to produce increased amounts of antiviralmediators. Once
the infection is established, the massively released virus progeny will
cause an exacerbated NF-κB activation that supports IAV replication
by ill-deﬁned mechanisms and causes an excessive proinﬂammatory
response in the lung which contributes to IAV-induced mortality.
The antiviral function of NF-κB in the early phase of IAV infection
also explains why IAVs employ several mechanisms to dampen or in-
hibit NF-κB activity. Deletion of the NS1 gene in IAV results in enhanced
IFN production in infected host cells, pointing to an IFN inhibiting func-
tion of the NS1 protein [80]. Accordingly, expression of the NS1 protein
antagonizes IAV-induced NF-κB activation and subsequent IFN synthe-
sis. Several studies show that the IFN antagonizing function of the NS1
protein depends on the IAV genotype [97,98]. For example, a virus con-
taining the 1918 pandemic NS1 gene wasmore efﬁcient at blocking the
IFN response than its parental IAV [97]. The IFN antagonizing function of
NS1 is mediated by several mechanisms, which are summarized in
Fig. 3. Co-immunoprecipitation experiments showed the constitutive
association of NS1 with the kinase domains of IKKα and IKKβ [99].
This binding interfereswith their function, asNS1 expression prohibited
their downstream effects. These include IKK-induced IκBα phosphory-
lation and IKKα-mediated phosphorylation of histone H3 S10 [99].
Besides its antagonizing activity on the classical NF-κB pathway,
the NS1 protein also impairs NIK-induced processing of p100 to the
DNA-binding p52 protein [99]. The relative contribution of the al-
ternative NF-κB signaling pathway for IAV replication is not clear,
as infection with IAV strains expressing the NS1 protein only modestly
activates the noncanonical NF-κB pathway [99,100]. The NS1 protein
was also reported to impair the transcriptional activity of other
transcription factors such as p53 [101] and immune-proteasome
pathways [98]. It is conceivable that NS1 will affect more cellular sig-
naling steps, as interactome screens have shown numerous cellular
binding partners for this viral protein including members of the PI3K
(phosphoinositide-3-kinase) and AKT signaling pathways [102,103].
Fig. 3. Cellular targets inhibited by the IAV protein NS1. The red lines point to the cellular targets that show reduced activity in the presence of NS1.
2759M.L. Schmitz et al. / Biochimica et Biophysica Acta 1843 (2014) 2754–2764Some IAV strains additionally express the accessory PB1-F2 protein
which stems from an alternative reading frame. One report showed
that PB1-F2 binds to IKKβ and impairs DNA-binding of NF-κB [104]. In
contrast, another study reports on an NF-κB intensifying activity of
PB1-F2 [105], so that more work is required to clarify its role on the
NF-κB system.
NF-κB activity will directly inﬂuence the IAV-infected host cell, but
its ability to trigger expression of chemokines and cytokines will also
regulate non-infected neighboring cells in a paracrine manner. This
complexity raises the need to study its relevance in suitable animal
systems, preferably in animals such as mice that can be genetically
manipulated. This will allow one to reveal the role of NF-κB in the broad
spectrum of IAV infection that ranges from asymptomatic or subclinical
infection to a severe viral pneumonia [106].
6. The role of NF-κB in HTLV-1 infection
HTLV-1 was the ﬁrst discovered human retrovirus [107] and is the
etiological agent for inﬂammatory diseases including the neurodegener-
ative disorder tropical spastic paraparesis/HTLV-1-associated myelopa-
thy and adult T-cell leukemia/lymphoma (ATL) [108,109]. Between 10
and 20 million people worldwide are infected with this virus and less
than 5% of the virus carriers develop ATL over decades [110]. At present
there is no treatment to cure this aggressive and lethal malignancy of
CD4+ T lymphocytes. HTLV-1 has a diploid genome, comprised of two
identical strands of positive sense RNA. Similar to other retroviruses
the genome contains two long terminal repeat (LTR) sequences that
drive expression of the viral structural proteins. The viruses also express
further regulatory proteins including Tax-1, Rex, p30, and HTLV-1 basic
leucine zipper factor (HBZ) [111]. The most intensively studied protein
is Tax-1, as it is required for the transforming ability of HTLV-1 [112].
Further evidence for the importance of Tax-1 came from the analysis
of transgenic Tax-1-expressing mice which develop tumors closely re-
sembling the phenotype of HTLV-1-induced ATL [113,114]. The Tax-1
protein impinges on a multitude of signaling pathways including NF-
κB as discussed in more detail below. The other HTLV-1-encoded pro-
teins are less intensively studied, but it is known that Rex, p30 and
HBZ negatively regulate the activity or expression of Tax-1. The Tax-1
protein reportedly interacts with more than 100 host cell proteins
including transcription factors, transcriptional regulators, chromatinmodiﬁers, protein kinases and proteins involved in cytoskeleton struc-
ture anddynamics [115]. In addition, numerous intracellular localizations
for Tax-1were reported including the nucleus [116], microtubule organi-
zation center [117], at the centrosome during mitosis [118,119] and in
the cytoplasm. Itwas also suggested that Tax-1 enters the secretory path-
way in a leaderless manner and can migrate from the endoplasmic re-
ticulum to the Golgi complex [120], thus even exerting extracellular
functions. The large number of interaction partners and intracellular lo-
calizations may help to explain the impact of Tax-1 on almost all cellular
signaling pathways including p53 activation and signaling via mitogen-
activated protein kinases, G-proteins and TGFβ (transforming growth
factor β) signaling [115].
From all these signaling pathways, NF-κB seems to be of special rel-
evance for the process of Tax-1-induced ATL, as suggested by several
ﬁndings: (i) Tax-1 mutants that are deﬁcient in the activation of NF-
κB fail to trigger Tax-1-induced cell proliferation and HTLV-1-induced
immortalization of T-cells [121,122]. (ii) Inhibition of NF-κB by various
approaches such as IKK inhibition and overexpression of dominant-
negative forms of IκBα or p100 protects cells from Tax-1-mediated
transformation in cell culture and animal experiments [123–126].
(iii) Inhibition of noncanonical NF-κB activation by knockout of the
gene coding for the p100/p52 proteins largely prevents tumorigenesis
in Tax-1 transgenicmice [127], thus clearly demonstrating the contribu-
tion of NF-κB for Tax-1-mediated oncogenesis. While these results col-
lectively show the relevance of the Tax-1–NF-κB axis for the induction
of tumorigenesis, it is interesting to note that expression of Tax-1 is
lost in the majority of all ATLs during the late stages of leukemogenesis
[128–130]. And also ATLs lacking Tax-1 expression show strong activa-
tion of canonical and noncanonical NF-κB pathways, implying the rele-
vance of Tax-1-independent mechanisms mediating chronic NF-κB
activity [131,132]. Proof-of-concept for the idea that ongoing consti-
tutive IKK activity per se is sufﬁcient to induce tumor formation was
revealed in a mouse model where constitutively active IKKβ was
expressed in intestinal epithelial cells. Expression of the active IKKβ
induces spontaneous tumors in aged mice [133], thus revealing that
IKK-induced tumors can be generated in the absence of additional
pro-tumorigenic events, at least in intestinal epithelial cells. As active
IKKs do not only feed in the NF-κB activation pathway (see Fig. 2), a
potential contribution of other IKK-regulated pathways for tumor
generation remains to be revealed in future studies.
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Early and Tax-1-dependent activation of NF-κB occurs by several
mechanismswhich are schematically summarized in Fig. 4. The relevance
of Tax-1 for the canonical NF-κB activation pathway was seen very early,
as NEMO was found to be essential for the NF-κB activating effects of
Tax-1 [134]. Further experiments showed that Tax-1 directly binds to
the adapter protein NEMO, thus causing the constitutive activation of
the IKK complex [135–137]. A fraction of Tax-1 is found in association
with Golgi-associated lipid rafts where this viral protein can recruit the
IKK complex to these membrane microdomains [138]. As the activation
status of IKKs can be determined with phospho-speciﬁc antibodies,
it would be interesting to see whether the lipid raft-associated IKKs
are active. Tax-1 can be modiﬁed by several posttranslational mod-
iﬁcations that regulate numerous aspects of its function. Ubiquitina-
tion of Tax-1 is important for NF-κB activation, since a Tax-1 mutant
unable to be ubiquitinated is impaired in NF-κB activation [139]. Tax-1
polyubiquitin chains are predominantly composed of K63-linked chains,
which do not lead to proteasomal degradation but rather allow binding
to ubiquitin-binding domains, thus allowing the increase of protein/
protein interactions [140]. As NEMO has the ability to bind to K63-
linked ubiquitin in its C terminus, this interactionwould even strengthen
NEMO/Tax-1 interactions [141]. The importance of the NEMO ubiquitin-
binding domain was shown for TNF-induced NF-κB activation [142]
and it will be interesting to test in the future whether the same holds
true for Tax-1-triggered NF-κB activation. The K63-branched ubiquitin
is attached to Tax-1 by the E2 ubiquitin-conjugating enzyme Ubc13
(ubiquitin conjugating 13). Deletion of the Ubc13 gene prevents Tax-1/
NEMO-binding and Tax-1-mediated NF-κB activation [143], but as Ubc13Fig. 4.Cellular targets regulatedby theHTLV-1Tax-1protein. Thedifferent localizations and inter
NF-κB pathway is indicated.also modiﬁes further members of the NF-κB activation pathway such as
TRAF6 [144] this defect may not be exclusively attributable to defective
Tax-1 ubiquitination. Interestingly, also one of the deubiquitinating
enzymes is shared between TRAF6 and Tax-1. The ubiquitin-speciﬁc
peptidase USP20 (ubiquitin speciﬁc peptidase) deubiquitinates Tax-1
and suppresses IL-1β- and Tax-1-induced NF-κB activation [145]. The
deubiquitination of Tax-1 can be also mediated by STAM-binding
protein-like 1 (STAMBPL1), which was identiﬁed in an RNA interfer-
ence screen [146]. Ubiquitination of Tax-1 also allows binding to the
NEMO-related protein Optineurin (OPTN) that functions in various
physiological processes including the IFN response. This protein com-
plex also contains the Tax-1 binding protein 1 (TAX1BP1) and the inter-
action between Tax-1 and OPTN requires the ubiquitin-binding activity
of OPTN and the ubiquitination sites of Tax-1 [147]. Immunoﬂuores-
cence studies show that Tax-1, OPTN and NEMO colocalize in Golgi-
associated lipid rafts, but further experiments such as sequential immu-
noprecipitations must clarify whether the two NEMO family members
are contained in the same or in distinct multi-protein complexes. In
the nucleus, a fraction of Tax-1 localizes to subnuclear domains which
overlap with structures containing the splicing regulator SC35 (serine/
arginine-rich splicing factor 2), a protein which is a commonly used
marker of spliceosomal speckles [148].
The nuclear structures containing Tax-1 also contain the NF-κB sub-
units p50 and p65 as well as the largest subunit of RNA polymerase II
and cyclin-dependent kinase CDK8 [149]. It will be highly interesting
to characterize the Tax-1-associated proteins in these nuclear bodies
in a more systematic way, although the limited solubility of these
chromatin-associated and tightly packed protein complexes is techni-
cally challenging. Expression of Tax-1 augments basal p65 acetylationactionpartners of Tax-1 are shown; its possible contribution to the induction of the atypical
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Brd4 (bromodomain-containing 4). Knockdownof Brd4 strongly impairs
Tax-1-inducedNF-κ-driven transcription [150], but it remains to be seen
whether Brd4 is a general or stimulus-speciﬁc NF-κB coactivator.
Tax-1 also induces the noncanonical NF-κB pathway as revealed by
Tax-1-induced IKKα-dependent processing of p100 to the p52 subunit.
Mice lacking the p100-encoding gene display a signiﬁcantly delayed
onset of Tax-1-induced tumorigenesis [127], showing the relevance
of noncanonical NF-κB signaling in ATL. The binding of Tax-1 to p100
allows the recruitment of IKKα, which in turn leads to phosphorylation-
dependent ubiquitination and processing of p100. This Tax-1-dependent
process also requires NEMO, as revealed by reconstitution experiments
in T cells lacking this adapter protein [151]. The role of NIKwas revealed
in an animal model using alymphoplasia (aly/aly) mice bearing a NIK
mutation [152]. HTLV-1 infection is signiﬁcantly reduced in aly/aly
mice and these animals do not maintain the provirus for 1 year [153],
pointing to the importance of functional NIK for HTLV-1 proliferation
and provirus maintenance. The protein levels of NIK are strongly
restricted by TRAF3-mediated polyubiquitination and proteasomal
degradation aswell as bymiR-31 [154,155]. Polycomb-mediated silenc-
ing ofmiR-31 in ATL cells leads to the stabilization of NIK, the activation
of noncanonical NF-κB activity and apoptosis resistance [155]. These
data also show that epigenetic programs impinge on oncogenic signal-
ing, a concept that may contribute to explain why only a fraction of
HTLV-1 infected cells develop to ATLs. The p52/RelB dimers suppress
expression of the gene encoding WW domain-containing oxidoreduc-
tase (WWOX). This tumor suppressor protein speciﬁcally inhibits Tax-
1-induced activation of the canonical pathway by blocking IKKα re-
cruitment to p65 and subsequent p65 phosphorylation [127], thereby
providing a mechanism that links canonical and noncanonical NF-κB
pathways in HTLV-1 Tax-1-mediated tumorigenesis.
Our understanding of Tax-1-induced activation of canonical and
noncanonical NF-κB signaling has steadily increased over the past
years. On the other hand, the mechanisms leading to maintained NF-
κB activation at the late stages of HTLV-1 infection after downregulation
of Tax-1 expression are still very incomplete. Many NF-κB target genes
are themselves strong activators of NF-κB, so that a number of cells
that have experienced sustained NF-κB activity maintain this transcrip-
tion factor active even after disappearance of the initial inducing agent.
Such a situation also occurs in rheumatoid arthritis where high levels
of cytokines entertain self-stimulatory regulatory circuits [156,157].
In addition to these mechanisms it can also be assumed that Tax-1-
expressing cells undergo epigenetic changes and chromatin remodeling
processes resulting in constitutive NF-κB activity. It will be therefore
highly interesting to investigate the contribution of these events in the
future. Tax-1 also promotes genetic instability by inducing DNA double
strand breaks during DNA replication. Tax-1 also inhibits homologous
recombination DNA repair and rather favors the error-prone non-
homologous end joining pathway [158,159]. Genomic instability
and mutation are enabling characteristics of cancer cells [160], but the
ongoing DNA damage might also trigger the atypical NF-κB signaling
pathway. It will thus be interesting to study whether characteristic
features of the atypical NF-κB pathway such as the occurrence of
SUMOylated NEMO in the nucleus are also found in ATLs.
8. Concluding remarks
Virus-encoded regulatory proteins such as Tax-1 and NS1 affect
many different host cell signaling pathways. They lack any known enzy-
matic function, but apparently bind to a large crowd of different cellular
proteins. This allows a precise manipulation of protein/protein interac-
tions, which are at the starting point ofmany signaling cascades. Impor-
tantly, the viral proteins also undergo numerous posttranslational
modiﬁcations which dictate their intracellular localization, function
and interaction with further binding partners. Detailed studies on the
occurrence and distribution of these modiﬁcations will help to explainthe characteristic multiplicity of functions displayed by viral proteins.
Thus the host cell enzymes controlling the posttranslational modiﬁca-
tions of viral proteins are potentially attractive antiviral target structures.
The ability of viral proteins to bind to so many interaction partners may
also be due to their structural ﬂexibility. A highly dynamic structure and
intrinsic disorder were suggested for the Tax-1 protein [115]. Further
ﬂexibility can be achieved by its association with chaperones such as
Hsp90 (heat shock protein 90) [161] and the prolyl cis–trans-isomerase
Pin1 [162], thus increasing the repertoire of binding partners. While the
cytosolic events leading to the activation of NF-κB have now reached a
level of detailed understanding, the regulation of this transcription factor
in the nucleus is still incomplete. It will be highly interesting to study
how RNA virus infection controls the (co)recruitment of transcription
factors and viral proteins to common or distinct chromatin loci by
ChIP-Seq (chromatin immunoprecipitation coupled to deep sequencing)
experiments. Also studies on the generation of an epigeneticmemory for
previous or persistent virus infections will reveal fascinating insights in
the future.
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